Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Panion & Bf Biotech Inc. manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners and 1 distinct art unit. This indicates that the company's current prosecution is technically concentrated within a single art unit.
BASQUILL, SEAN M is the busiest examiner, overseeing 1 pending office action. Since there are 2 distinct examiners for the active matters, the workload is divided equally. Each examiner is responsible for the prosecution of exactly half of the pending matters in this portfolio.
The presence of 1 distinct art unit for the 2 pending office actions means that the company is dealing with a single technical group. Practitioners should focus on the specific examination standards of the art unit while managing the 2 distinct examiners. This Biotechnology & Pharmaceuticals portfolio currently has a very narrow and focused prosecution footprint, with 1 examiner assigned per case.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BASQUILL, SEAN M | 1 | 38.8% | +21.7% |
| BABSON, NICOLE PLOURDE | 1 | 46.6% | +33.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18580162 | CONTROLLED-RELEASE ORAL FORMULATION AND PREPARATION METHOD THEREOF | BABSON, NICOLE PLOURDE | 22d |
| 18826114 | TOPICAL COMPOSITION AND MANUFACTURING METHOD AND USE THEREOF | BASQUILL, SEAN M | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18826114 | TOPICAL COMPOSITION AND MANUFACTURING METHOD AND USE THEREOF | BASQUILL, SEAN M | — | §103 | Non-Final OA | — | Pending | Sep 05, 2024 |
| 18580162 | CONTROLLED-RELEASE ORAL FORMULATION AND PREPARATION METHOD THEREOF | BABSON, NICOLE PLOURDE | 1619 | §103 | Final Rejection | 22d | Pending | Jan 18, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial